Extrafine beclomethasone dipropionate breath-actuated inhaler (400 μG/day) versus budesonide dry powder inhaler (800 μG/day) in asthma

International Journal of Clinical Practice

Volumn 55, Issue 2, 2001, Pages 100-106

  Reichel, W ^a   Dahl, R ^a   Ringdal, N ^a   Zetterstrom, O ^a   Van den Elshout, F J J ^a   Laitinen, L A ^a  

^a Lungen Bronchialheilkunde Allergol   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; NORFLURANE;

ADULT; AGED; ARTICLE; ASTHMA; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BUDESONIDE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PEAK EXPIRATORY FLOW RATE; SLEEP; VITAL CAPACITY;

EID: 0035081066     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. The Montreal Protocol on substances that deplete the ozone layer: Final act (Nairobi: UNEP, 1987)
2. The effect of flow rate on particle size and fine particle dose with CFC-free breath-actuated steroid inhalers
3. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers
4. Efficacy response of inhaled beclomethasone in asthma is proportional to dose and is improved by formulation with a new propellant
5. Enhanced delivery performance of HFA-beclomethasone from a breath-activated metered dose inhaler
6. Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma
7. Systemic effects of high dose inhaled steroids: Comparison of beclomethasone dipropionate and budesonide in healthy subjects
8. High-dose inhaled steroids in the management of asthma: A comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial responsiveness and the adrenal function
9. Comparison of inhaled corticosteroids
10. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
11. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma
12. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma
13. Effectiveness of low doses (50 μg and 100 μg twice daily) of beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma
14. -1 delivered as an extrafine aerosol in adults with moderate asthma
15. Inflammatory and structural changes in the small airways in bronchial asthma
16. Assessment of airway inflammation in asthma
17. How big are the bronchioles?
18. The current laboratory determination of 'respirable mass' is not clinically relevant
19. Comparison of the in vitro delivery characteristics of three steroid aerosol delivery systems
20. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
21. Lung deposition of budesonide inhaled via Turbuhaler: A comparison with terbutaline sulphate in normal subjects
22. Lung deposition of budesonide from turbuhaler in asthmatic children
23. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines
24. Acute safety of the CFC-free propellant HFA-134a from a pressurised metered dose inhaler
25. Twenty-eight day doubleblind safety of an HFA-134a inhalation aerosol system in healthy subjects
26. Safety assessment of the HFA propellant and the new inhaler
27. Preclinical safety of propellant HFA-134a and Airomir
28. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol
29. The transition in practice: Health professionals and patients